Information regarding the availability and approval of Qbrexza in Australia is not available in the provided text.
Has Qbrexza been approved for use in other countries?
Qbrexza is approved in the United States for the topical treatment of primary axillary hyperhidrosis in patients aged 9 years and older [1].
What is Qbrexza used to treat?
Qbrexza is a prescription medication used to treat excessive sweating, also known as primary axillary hyperhidrosis, in individuals aged 9 and above [1].
How does Qbrexza work?
Qbrexza contains the active ingredient, glycopyrronium tosylate, which is an anticholinergic medicine. It works by blocking the action of acetylcholine, a chemical messenger that stimulates sweat glands [1].
What are the potential side effects of Qbrexza?
Common side effects of Qbrexza may include dry mouth, urinary retention, blurred vision, and dilated pupils [1].
What are the risks associated with Qbrexza?
There are risks associated with Qbrexza, particularly concerning its anticholinergic properties. Patients with certain medical conditions may be at higher risk. It is important to discuss any pre-existing conditions with a healthcare provider [1].
Who manufactures Qbrexza?
Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, manufactures Qbrexza [1].
Where can I find more information about Qbrexza?
More detailed information about Qbrexza, including prescribing information and patient resources, can be found on the product's official website or through a healthcare professional [1]. Information about drug patents and exclusivity can be found on DrugPatentWatch.com [2].
Sources
1. Dermira, Inc. Qbrexza [Package Insert]. 2018.
2. DrugPatentWatch.com.